I. OVERVIEW OF THE FUNDING OPPORTUNITY

Program Announcement for the Department of Defense
Defense Health Program
Congressionally Directed Medical Research Programs
Duchenne Muscular Dystrophy Research Program

Idea Development Award

Announcement Type: Initial

Funding Opportunity Number: HT942524DMDRPIDA
Assistance Listing Number: 12.420 Military Medical Research and Development

SUBMISSION AND REVIEW DATES AND TIMES

- Pre-Application (Letter of Intent) Submission Deadline: 5:00 p.m. Eastern time (ET), August 1, 2024
- Application Submission Deadline: 11:59 p.m. ET, August 22, 2024
- End of Application Verification Period: 5:00 p.m. ET, August 27, 2024
- Peer Review: November 2024
- Programmatic Review: February 2025

This program announcement must be read in conjunction with the General Application Instructions, version 901. The General Application Instructions document is available for downloading from the Grants.gov funding opportunity announcement by selecting the “Package” tab, clicking “Preview,” and then selecting “Download Instructions.”
# TABLE OF CONTENTS

I. OVERVIEW OF THE FUNDING OPPORTUNITY ....................................................... 1  
II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY .............. 3  
  II.A. Program Description ............................................................................... 3  
    II.A.1. FY24 DMDRP Focus Areas ................................................................. 3  
    II.A.2. Award History ................................................................................... 4  
  II.B. Award Information .................................................................................. 4  
  II.C. Eligibility Information ............................................................................ 7  
    II.C.1. Eligible Applicants ............................................................................ 7  
    II.C.2. Cost Sharing ..................................................................................... 8  
    II.C.3. Other ............................................................................................... 8  
  II.D. Application and Submission Information .................................................. 8  
    II.D.1. Location of Application Package ....................................................... 8  
    II.D.2. Content and Form of the Application Submission .............................. 9  
      II.D.2.a. Step 1: Pre-Application Submission .......................................... 10  
      II.D.2.b. Step 2: Full Application Submission .......................................... 11  
      II.D.2.c. Applicant Verification of Full Application Submission in eBRAP .... 18  
    II.D.3. Unique Entity Identifier (UEI) and System for Award Management (SAM) 19  
    II.D.4. Submission Dates and Times .............................................................. 19  
    II.D.5. Funding Restrictions ......................................................................... 19  
    II.D.6. Other Submission Requirements ...................................................... 19  
  II.E. Application Review Information ............................................................... 20  
    II.E.1. Criteria ............................................................................................ 20  
    II.E.2. Application Review and Selection Process ....................................... 22  
    II.E.3. Integrity and Performance Information .......................................... 23  
  II.F. Federal Award Administration Information .............................................. 23  
    II.F.1. Federal Award Notices ................................................................. 23  
    II.F.2. PI Changes and Award Transfers ..................................................... 24  
    II.F.3. Administrative and National Policy Requirements ............................ 24  
    II.F.4. Reporting ......................................................................................... 25  
  II.G. Federal Awarding Agency Contacts ........................................................ 25  
    II.G.1. eBRAP Help Desk ........................................................................... 25  
    II.G.2. Grants.gov Contact Center .............................................................. 26  
  II.H. Other Information ................................................................................ 26  
    II.H.1. Program Announcement and General Application Instructions Versions 26  
    II.H.2. Administrative Actions .................................................................... 26  
    II.H.3. Full Application Submission Checklist ............................................ 28  

APPENDIX 1: ACRONYM LIST .............................................................................. 29
II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY

II.A. Program Description

The U.S. Army Medical Research Acquisition Activity (USAMRAA) is soliciting applications to the fiscal year 2024 (FY24) Duchenne Muscular Dystrophy Research Program (DMDRP) using delegated authority provided by United States Code, Title 10, Section 4001 (10 USC 4001). The Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC) is the program management agent for this funding opportunity. Congress initiated the DMDRP in 2011 to provide support for research of high potential impact and exceptional scientific merit. Appropriations for the DMDRP from FY11 through FY23 totaled $69.6 million (M). The FY24 appropriation is $10.0M.

*The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public.*

The vision of the FY24 DMDRP is to preserve and improve the function and quality of life, and to extend the life span of all individuals with Duchenne Muscular Dystrophy (DMD). As such, the DMDRP seeks to support discovery, development, and delivery of therapeutics for DMD at all stages of the disease for the benefit of military Families and the general public. Additionally, the DMDRP supports the efforts of the National Institutes of Health (NIH) Muscular Dystrophy Coordinating Committee (MDCC) and the [2015 MDCC Action Plan for the Muscular Dystrophies](#), which prioritizes the needs to improve treatments and reduce the disease burden for muscular dystrophy, including DMD.

II.A.1. FY24 DMDRP Focus Areas

To meet the intent of the funding opportunity, applications *must address opportunities and challenges in the development of safe and effective therapies that focus on primary pathology of DMD.* Therapies that will be efficacious across the life span, including infants, toddlers, and non-ambulatory individuals, are strongly encouraged.

Studies proposed under this award *may* include:

- Preclinical testing of combination therapies with small molecules and/or biologics that have existing human clinical data in DMD or repurposed from other disorders

- Optimized delivery to specific tissues or cell types, including targeting to skeletal muscle, heart, brain, and muscle stem cells (e.g., ligand-assisted delivery, tissue-specific promoters, nanoparticles, alternative vectors, identification of biological barriers to delivery)

- Strategies to overcome preexisting immunity and to facilitate repeat administration of biologic therapies (e.g., immune system modulation, vector modification)

- Cell-based therapies, including, but not limited to, selection of novel cell types, expansion, cell delivery and homing, differentiation, and integration
• Non-genomic therapies that are downstream from the genetic defect to address disease pathogenesis (e.g., mitochondrial dysfunction, inflammation, fibrosis, fatty infiltration, etc.)

• Research that will inform and improve therapy in older individuals ineligible for currently approved or in-development therapeutics (e.g., age, type of mutations, seropositivity, rare exons)

• Discovery and validation of novel targets, including genetic modifiers and factors that determine the selective vulnerability/resistance of individual muscles, especially in humans

• Validation of novel small animal models that better recapitulate the human pathophysiology to study effectiveness of new therapeutics

• Therapies that address muscle regeneration deficits

Studies in the following research areas will not be supported by this award mechanism:

• Studies testing the efficacy of candidate therapeutics without a strong mechanistic rationale

• Evaluation of vectors or delivery technologies already prevalent in research studies (e.g., AAV9)

II.A.2. Award History

The DMDRP Idea Development Award (IDA) mechanism was first offered in FY19. Since then, 175 IDA applications have been received, and 39 have been recommended for funding.

II.B. Award Information

The FY24 DMDRP IDA promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with DMD. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale.

New Investigators: The FY24 DMDRP IDA mechanism encourages applications from independent investigators in the early stages of their careers (i.e., within 10 years of their first faculty appointment or equivalent) or applications from established investigators new to DMD research.

• The New Investigator – Early Stage category is designed to allow applicants early in their faculty appointments to compete for funding separately from established investigators.

• The New Investigator – Transitioning category is designed to allow investigators in an area other than muscular dystrophy, at or above the level of Assistant Professor, seeking to transition to a career in DMD, thereby bringing their expertise to the field.
Applications from New Investigators and Established Investigators will be peer and programmatically reviewed separately. Principal Investigators (PIs) using the New Investigator – Early Stage category or New Investigator – Transitioning category are strongly encouraged to strengthen their applications by collaborating with investigators experienced in DMD research and/or possessing other relevant expertise. It is the responsibility of the applicant to describe how the included collaboration will augment the PI’s expertise to best address the research question. All applicants for the New Investigator categories must meet the specific eligibility criteria described in Section II.C, Eligibility Information.

**Preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches are required. Preliminary data may include unpublished results from the laboratory of the PI, research team or collaborators named on the application.**

Key elements of this award are as follows:

- **Innovation:** Research deemed innovative may introduce a new paradigm, challenge current paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities.

- **Impact:** Research that has high potential impact may lead to major advancements and significantly accelerate progress toward improving outcomes for individuals with DMD.

*It is the responsibility of the PI to clearly and explicitly articulate the project’s innovation and its potential impact on DMD. The project’s impact to both DMD research and to individuals with DMD should be articulated, even if clinical impact is not an immediate outcome. Applications that demonstrate exceptional scientific merit but lack innovation and high potential impact do not meet the intent of the IDA.*

**Clinical trials are not allowed under this funding opportunity.**

*A clinical trial is defined* in 45 CFR 46.102 as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.

**Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.**

*For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:*

(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b)
diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.

(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.

(3) Outcomes research and health services research that do not fit under the definition of clinical trial.

Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under §46.104(d)(4) of the Common Rule.

**Guidelines for Animal Research:** All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. The standards are described in Landis SC, et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature, 490:187-191 (www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. Applicants should consult the Animal Research: Reporting In Vivo Experiments (ARRIVE) guidelines 2.0 to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The ARRIVE guidelines 2.0 can be found at https://arriveguidelines.org/arrive-guidelines.

The funding instrument for awards made under the program announcement will be grants (31 USC 6304).

The anticipated direct costs budgeted for the entire period of performance for an FY24 DMDRP Idea Development Award should not exceed $350,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

Awards supported with FY24 funds will be made no later than September 30, 2025.

The CDMRP expects to allot approximately $4.48M to fund approximately eight Idea Development Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.
II.C. Eligibility Information

II.C.1. Eligible Applicants

II.C.1.a. Organization: Extramural and Intramural organizations are eligible to apply, including foreign or domestic organizations, for-profit and non-profit organizations, and public entities.

Extramural Organization: An eligible non-DOD organization. Examples of extramural organizations include academic institutions, biotechnology companies, foundations, federal government organizations other than the DOD (i.e., intragovernmental organizations), and research institutes.

Intramural DOD Organization: Refers specifically to DOD organizations including DOD laboratories, DOD military treatment facilities, and/or DOD activities embedded within a civilian medical center.

Awards are made to eligible organizations, not to individuals. Refer to the General Application Instructions, Appendix 1, for additional recipient qualification requirements.

II.C.1.b. Principal Investigator

Although a PI may be eligible for the New Investigator – Early Stage, New Investigator – Transitioning, and Established Investigator categories, only one category may be chosen; the choice of application category is at the PI’s discretion, provided the eligibility criteria are met.

- Established Investigator

  The PI must be an independent investigator at or above the level of Assistant Professor (or equivalent).

- New Investigator – Early Stage

  By the application submission deadline date, the PI must:

  - Not have previously received a DMDRP IDA.
  - Be an independent investigator at or above the level of Assistant Professor (or equivalent) who is within 10 years of their first faculty appointment (or equivalent) by the time of the application submission deadline. Lapses in research time or appointments, as denoted in the biographical sketch, may be articulated in the application.

- New Investigator – Transitioning

  - Be an investigator in an area other than muscular dystrophy at or above the level of Assistant Professor seeking to transition to a career in DMD, thereby bringing their expertise to the field.
○ Investigators must pursue an active line of research in DMD and commit at least 10% minimum effort during each budget year toward the proposed DMD research project.

PIs using the New Investigator categories are strongly encouraged to strengthen their applications by collaborating with investigators experienced in DMD research and/or possessing other relevant expertise. It is the responsibility of the applicant to describe how the included collaboration will augment the PI’s expertise to best address the research question.

An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by or affiliated with an eligible organization.

II.C.2. Cost Sharing

Cost sharing/matching is not an eligibility requirement.

II.C.3. Other

Organizations must be able to access .gov and .mil websites to fulfill the financial and technical deliverable requirements of the award and submit invoices for payment.

Refer to Section II.H.2, Administrative Actions, for a list of administrative actions that may be taken if a pre-application or full application does not meet the administrative, eligibility, or ethical requirements defined in this program announcement.

II.D. Application and Submission Information

II.D.1. Location of Application Package

Submission is a two-step process requiring both a pre-application submitted via the Electronic Biomedical Research Application Portal (eBRAP.org) and a full application (eBRAP.org or Grants.gov). Depending on the type of submission (i.e., extramural vs. intramural), certain aspects of the submission process will differ.

The CDMRP uses two portal systems to accept pre- and full application submissions.

eBRAP (https://ebrap.org) is a secure web-based system that allows PIs and/or organizational representatives from both extra- and intramural organizations to receive communications from the CDMRP and submit their pre-applications. Additionally, eBRAP allows extramural applicants to view and verify full applications submitted to Grants.gov and allows intramural DOD applicants to submit and verify full applications following their pre-application submission.

Grants.gov (https://grants.gov) is a federal system that must be used by funding agencies to announce extramural grant applications. Full applications for CDMRP funding opportunities can only be submitted to Grants.gov after submission of a pre-application through eBRAP.
Extramural Submission: An application submitted by an extramural organization for an extramural or intramural PI working within an extramural or intramural organization. For example, a research foundation submitting an application for a DOD employee working within a DOD organization would be considered an extramural submission and should follow instructions specific to extramural submissions. Download application package components for HT942524/MDRPIDA from Grants.gov (https://grants.gov). Full applications from extramural organizations must be submitted through Grants.gov.

Intramural Submission: An application submitted by an intramural DOD organization for an investigator employed by that organization. Intramural DOD organizations may submit full applications to either eBRAP or Grants.gov. Download application package components for HT942524/MDRPIDA from the anticipated submission portal eBRAP (https://ebrap.org) or Grants.gov.

The submission process should be started early to avoid missing deadlines. Regardless of submission type or portal used, all pre- and full application components must be submitted by the deadlines stipulated on the first page of this program announcement. There are no grace periods for deadlines; failure to meet submission deadlines will result in application rejection. The USAMRAA cannot make allowances/exceptions for submission problems encountered by the applicant organization using system-to-system interfaces with Grants.gov.

II.D.2. Content and Form of the Application Submission

Submitting applications that propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application(s).
Unnecessary duplication of funding, or accepting funding from more than one source for the same research, is prohibited. See CDMRP’s full position on research duplication at https://cdmrp.health.mil/funding/researchDup.

Including classified research data within the application and/or proposing research that may produce classified outcomes, or outcomes deemed sensitive to national security concerns, may result in application withdrawal. Refer to the General Application Instructions, Appendix 7, Section B.

FY24 DMDRP Programmatic Panel members should not be involved in any pre-application or full application. For questions related to panel members and pre-applications or applications, refer to Section II.H.2.e, Withdrawal, or contact the eBRAP Help Desk at help@eBRAP.org or 301-682-5507.

II.D.2.a. Step 1: Pre-Application Submission

All pre-application components must be submitted by the PI through eBRAP (https://eBRAP.org/).

During the pre-application process, eBRAP assigns each submission a unique log number. This unique log number is required during the full application submission process. The eBRAP log number, application title, and all information for the PI, Business Official(s), performing organization, and contracting organization must be consistent throughout the entire pre-application and full application submission process. Inconsistencies may delay application processing and limit or negate the ability to view, modify, and verify the application in eBRAP. If any changes need to be made, the applicant should contact the eBRAP Help Desk at help@eBRAP.org or 301-682-5507 prior to the application submission deadline.

When starting the pre-application, applicants will be asked to select a “Mechanism Option”. Please be sure to select the correct option appropriate to your pre-application:

<table>
<thead>
<tr>
<th>Application Includes:</th>
<th>Select Option:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Established Investigator: An independent investigator at or above the level of Assistant Professor (or equivalent)</td>
<td>Idea Development Award – Established Investigator Option</td>
</tr>
<tr>
<td>New Investigator-Early Stage: An independent investigator at or above the level of Assistant Professor (or equivalent) and within 10 years of their first faculty appointment (or equivalent)</td>
<td>Idea Development Award – New Investigator-Early Stage Option</td>
</tr>
<tr>
<td>New Investigator-Transitioning: An investigator in an area other than muscular dystrophy at or above the level of Assistant Professor seeking to transition to a career in DMD</td>
<td>Idea Development Award – New Investigator-Transitioning Option</td>
</tr>
</tbody>
</table>
II.D.2.a.i. Pre-Application Components

Pre-application submissions must include the following components (refer to the General Application Instructions, Section III.B, for additional information on pre-application submission):

- **Letter of Intent (LOI) (one-page limit):** Provide a brief description of the research to be conducted.

LOIs are used for program planning purposes only (e.g., reviewer recruitment) and will not be reviewed during either the peer or programmatic review. *An invitation to submit a full application is NOT provided after LOI submission. Applicants are encouraged to develop pre-application and full application components concurrently and submit a full application AFTER successful submission of the pre-application.*

II.D.2.b. Step 2: Full Application Submission

II.D.2.b.i. Full Application Submission Type

**Extramural Submissions:** Full applications from extramural organizations *must* be submitted through Grants.gov Workspace. Full applications from extramural organizations, including non-DOD federal organizations, received through eBRAP will be withdrawn. Refer to the General Application Instructions, Section IV, for considerations and detailed instructions regarding extramural full application submission.

**Intramural Submissions:** Intramural DOD organizations may submit full applications through either eBRAP or Grants.gov. There is no preference from the CDMRP for which submission portal is utilized; submission through one portal or the other does not provide the application any advantage during the review process. Intramural DOD organizations that choose to submit through Grants.gov should follow Extramural Submission instructions. Intramural DOD organizations that are unable to submit through Grants.gov should submit through eBRAP. For the remainder of this program announcement, it will be assumed intramural DOD submissions will proceed through eBRAP. Refer to the General Application Instructions, Section V, for considerations and detailed instructions regarding intramural DOD full application submission.

II.D.2.b.ii. Full Application Submission Components

Each application submission must include the completed full application package for this program announcement. See Section II.H.3 of this program announcement for a checklist of the required application components.

(a) **SF424 Research & Related Application for Federal Assistance Form (Extramural Submissions Only):** Refer to the General Application Instructions, Section IV.B, for detailed information.
(b) Attachments:

Each attachment to the full application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines listed in the General Application Instructions, Appendix 2.

- **Attachment 1: Project Narrative (10-page limit):** Upload as “ProjectNarrative.pdf”. The page limit of the Project Narrative applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs (uniform resource locators) that provide additional information that expands the Project Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the application.

Describe the proposed project in detail using the outline below.

- **Background:** Explain how the novel idea is supported by sound logical reasoning and strong mechanistic rationale that is relevant to DMD. Cite relevant, published literature and any applicable preliminary data.

- **Hypothesis or Objective:** State the hypothesis to be tested or the objective to be reached.

- **Specific Aims:** Concisely explain the project’s specific aims to be supported by this application. If the proposed research is part of a larger study, present only tasks that this award would fund.

- **Research Strategy and Feasibility:** Describe the experimental design, methods, and analyses including appropriate controls, in sufficient detail for evaluation. Clearly describe how data will be collected and analyzed in a manner that is consistent with the study objectives. Address potential limitations and present alternative methods and approaches. If animal studies are proposed, describe how they will be conducted in accordance with the ARRIVE guidelines 2.0 (https://arriveguidelines.org/arrive-guidelines) to achieve reproducible and rigorous results, including the choice of model and the endpoint/outcomes to be measured. If human subjects or human biological samples will be used, include a detailed plan for the recruitment of subjects or the acquisition of samples. For clinical research, describe the strategy for the inclusion of women and minorities in the clinical research appropriate to the objectives of the study, including a description of the composition of the proposed study population in terms of sex/gender, race, and/or ethnicity, and an accompanying rationale for the selection of subjects. *This award cannot be used to conduct clinical trials.*

- **Statistical Analysis Plan:** Describe the statistical analysis plan for the resulting outcomes. If applicable, include a complete power analysis to demonstrate the sample size is appropriate to meet the objectives of the study. Describe how data will be reported and how it will be assured that the documentation will support a regulatory filing with the Food and Drug Administration (FDA), if applicable.
Attachment 2: Supporting Documentation: Combine and upload as a single file named “Support.pdf”. Start each document on a new page. The Supporting Documentation attachment should not include additional information such as figures, tables, graphs, photographs, diagrams, chemical structures, or drawings. These items should be included in the Project Narrative.

There are no page limits for any of these components unless otherwise noted. Include only those components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application.

- References Cited: List the references cited (including URLs, if available) in the Project Narrative using a standard reference format.

- List of Abbreviations, Acronyms, and Symbols: Provide a list of abbreviations, acronyms, and symbols.

- Facilities, Existing Equipment, and Other Resources: Describe the facilities and equipment available for performance of the proposed project and any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether government-furnished facilities or equipment are proposed for use. If so, reference should be made to the original or present government award under which the facilities or equipment items are now accountable. There is no form for this information.

- Publications and/or Patents: Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.

- Letters of Organizational Support: Provide a letter (or letters, if applicable) signed by the Department Chair or appropriate organization official, confirming the laboratory space, equipment, support for 10% effort during each budget year toward the proposed DMD research project for the New Investigator – Transitioning category and other resources available for the project. Letters of support not requested in the program announcement, such as those from members of Congress, do not impact application review or funding decisions.

- Letters of Collaboration (if applicable): Provide a signed letter from each collaborating individual and/or organization demonstrating that the PI has the support and resources necessary for the proposed work. If an investigator at an intramural DOD organization is named as a collaborator on a full application submitted through an extramural organization, the application must include a letter from the collaborator’s Commander or Commanding Officer at the intramural DOD organization authorizing the collaborator’s involvement.
- **Intellectual Property:** Information can be found in the 2 CFR 200.315, “Intangible Property.”

  - **Intellectual and Material Property Plan (if applicable):** Provide a plan for resolving intellectual and material property issues among participating organizations.

  - **Commercialization Strategy (if applicable):** Describe the commercialization plan. The plan should include intellectual property, market size, financial analysis, strengths and weaknesses, barriers to the market, competitors, and management team. Discuss the significance of this development effort, when it can be anticipated, and the potential commercial use for the technology being developed.

- **Inclusion of Women and Minorities:** Provide an anticipated enrollment table(s) for the inclusion of women and minorities appropriate to the objectives of the study with the proposed enrollment distributed on the basis of sex/gender, race, and ethnicity. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, gender, ethnicity, or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement. The Public Health Service (PHS) Inclusion Enrollment Report is a three-page fillable PDF form, which can be downloaded from eBRAP at [https://ebrap.org/eBRAP/public/Program.htm](https://ebrap.org/eBRAP/public/Program.htm).

- **DOD Data Management Plan (two-page limit is recommended):** Describe the data management plan in accordance with Section 3.c, Enclosure 3, DoD Instructions 3200.12. Do not duplicate the Data and Research Resources Sharing Plan. Refer to General Application Instructions, Section IV.B, Attachments Form, Attachment: Supporting Documentation, for detailed information regarding Data Management Plan content.

- **Use of DOD Resources (if applicable):** Provide a letter of support signed by the lowest-ranking person with approval authority confirming access to active-duty military populations and/or DOD resources or databases.

- **Use of U.S. Department of Veterans Affairs (VA) Resources (if applicable):** Provide a letter of support signed by the VA Facility Director(s) or individual designated by the VA Facility Director(s), such as the Associate Chief of Staff for Research and Development (ACOS/R&D) or Clinical Service Chief, confirming access to VA patients, resources, and/or VA research space. If the VA-affiliated non-profit corporation is not identified as the applicant organization for administering the funds, include a letter from the VA ACOS/R&D confirming this arrangement and identifying the institution that will administer the funds associated with the proposed research.

- **Attachment 3: Technical Abstract (one-page limit):** Upload as “TechAbs.pdf”. The technical abstract is used by all reviewers. Abstracts of all funded research projects will be posted publicly. Use only characters available on a standard QWERTY keyboard.
Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

Technical abstracts should be written using the outline below. Clarity and completeness within the space limits are highly important.

- **Background:** Present the scientific rationale behind the proposed research project.

- **Hypothesis/Objective(s):** State the hypothesis to be tested and/or objective(s) to be reached. Provide evidence or scientific rationale that supports the hypothesis/objective(s).

- **Specific Aims:** State the specific aims of the study.

- **Study Design:** Describe the study design, including appropriate controls.

- **Innovation:** Briefly describe how the proposed project is innovative.

- **Impact:** Summarize the potential impact of the proposed project toward the development of safe and effective macromolecular and cellular therapies for DMD.

○ **Attachment 4: Lay Abstract (one-page limit): Upload as “LayAbs.pdf”**. The lay abstract is used by all reviewers, and addresses issues of particular interest to the affected community. Abstracts of all funded research projects will be posted publicly. Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed. **Do not duplicate the technical abstract.**

Lay abstracts should address the points outlined below in a manner that will be readily understood by readers without a background in science or medicine. Avoid overuse of scientific jargon, acronyms, and abbreviations.

- Describe the ultimate applicability of the research.
  - What types of patients will it help and how will it help them?
  - What are the potential clinical applications, benefits, and risks? If the research is too basic for clinical applicability, describe the interim outcomes expected and their applicability to the field.
  - What is the projected time anticipated to achieve a clinically relevant outcome?
  - What are the likely contributions of this study to advancing the field of DMD research?
Attachment 5: Statement of Work (three-page limit): Upload as “SOW.pdf”. Refer to the eBRAP “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) for the suggested SOW format and recommended strategies for assembling the SOW.

For the IDA, refer to “Example: Assembling a Generic Statement of Work” for guidance on preparing the SOW. Use the “Suggested SOW Format” to develop the SOW for the proposed research. Submit as a PDF.

Attachment 6: Impact Statement (one-page limit): Upload as “Impact.pdf”. The Impact Statement should be written in plain language for lay persons. Describe how the proposed project is expected to make an important and original contribution to addressing opportunities and challenges in the development of safe and effective macromolecular and cellular therapies that address primary pathology of DMD. The relevance of all research, including basic, should relate to patient outcomes and how it benefits those affected by DMD. Explain how the proposed research will significantly accelerate progress towards improving outcomes for individuals with DMD.

Attachment 7: Innovation Statement (one-page limit): Upload as “Innovation.pdf”. Describe how the proposed work is innovative. Research deemed innovative may introduce a new paradigm, challenge current paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities (i.e., concept or question, research methods or technologies, adaptations of existing methods or technologies, or other ways). Describe how the proposed research represents more than an incremental advance beyond ongoing research and published data.

Attachment 8: Data and Research Resources Sharing Plan (one-page limit): Upload as “Sharing.pdf”. Describe how data and resources generated during the performance of the project will be shared with the research community. State whether the proposed plan for data sharing includes databases most relevant to DMD and whether the plan describes organizational and technical capabilities sufficient to share project data in a timely manner. Refer to the General Application Instructions, Appendix 2, Section K, for more information about the CDMRP expectations for making data and research resources publicly available. Include plans for making raw data publicly available in appropriate databases (e.g., database of Genotypes and Phenotypes, Gene Expression Omnibus) at the time of publication or at the time of conclusion of the funding. The government reserves the right to identify repositories for submission of data for archive. Any costs associated with submission will be addressed during award negotiations.

Attachment 9: Letter of Eligibility (New Investigator – Early Stage Only) (one-page limit): Upload as “Eligibility.pdf”. Provide a letter signed by the PI and the Department Chair, Dean, or equivalent official verifying that the eligibility requirements will be met by the application submission deadline. The letter should verify that the PI is an independent investigator at or above the level of Assistant Professor (or equivalent); within 10 years of their first faculty appointment, including the date the PI began their
first faculty appointment (Month/Year); and the PI has not previously received an DMDRP IDA (refer to Section II.C, Eligibility Information).

○ **Attachment 10: Representations (Extramural Submissions Only):** Upload as “RequiredReps.pdf”. All extramural applicants must complete and submit the Required Representations template available on eBRAP ([https://ebrap.org/eBRAP/public/Program.htm](https://ebrap.org/eBRAP/public/Program.htm)). For more information, see the General Application Instructions, Appendix 8, Section B, Representations.

○ **Attachment 11: Suggested Intragovernmental/Intramural Budget Form (if applicable):** Upload as “IGBudget.pdf”. If an intramural DOD organization will be a collaborator in performance of the project, complete a separate budget using the “Suggested Intragovernmental/Intramural Budget Form”, available for download on the eBRAP “Funding Opportunities & Forms” web page ([https://ebrap.org/eBRAP/public/Program.htm](https://ebrap.org/eBRAP/public/Program.htm)). The budget should cover the entire period of performance for each intramural DOD site and include a budget justification as instructed. The total costs per year for each subaward (direct and indirect costs) should be included on the Grants.gov Research & Related Budget Form under subaward costs. Refer to the General Application Instructions, Section V.A.(e), for additional information and considerations.

(c) **Research & Related Personal Data:** For extramural submissions, refer to the General Application Instructions, Section IV.B.(c), and for intramural submissions, refer to the General Application Instructions, Section V.A.(c), for detailed instructions.

(d) **Research & Related Senior/Key Person Profile (Expanded):** For extramural submissions, refer to the General Application Instructions, Section IV.B.(d), and for intramural submissions, refer to the General Application Instructions, Section V.A.(d), for detailed instructions.

○ **PI Biographical Sketch (five-page limit):** Upload as “Biosketch_LastName.pdf”. The suggested biographical sketch format is available on the “Funding Opportunities & Forms” web page ([https://ebrap.org/eBRAP/public/Program.htm](https://ebrap.org/eBRAP/public/Program.htm)) in eBRAP. The NIH Biographical Sketch may also be used. All biographical sketches should be submitted in uneditable PDF format.

  – Include examples of accomplishments such as products, patents, or licenses; presentations at international scientific meetings; awards or other forms of acknowledgement for the PI’s achievements.

  – Highlight any publications in high impact journals

○ **PI Previous/Current/Pending Support (no page limit):** Upload as “Support_LastName.pdf”.

○ **Key Personnel Biographical Sketches (five-page limit each):** Upload as “Biosketch_LastName.pdf”.
○ Key Personnel Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf”.

(e) Research & Related Budget: For extramural submissions, refer to the General Application Instructions, Section IV.B.(e), and for intramural submissions, refer to the General Application Instructions, Section V.A.(e), for detailed instructions.

○ Budget Justification (no page limit): For extramural submissions, refer to the General Application Instructions, Section IV.B.(e), Section L, for instructions. For intramural submissions, refer to General Application Instructions, Section V.A.(e), Budget Justification Instructions.

(f) Project/Performance Site Location(s) Form: For extramural submissions, refer to the General Application Instructions, Section IV.B.(f), and for intramural submissions, refer to the General Application Instructions, Section V.A.(f), for detailed instructions.

(g) Research & Related Subaward Budget Attachment(s) Form (if applicable, Extramural Submissions Only): Refer to the General Application Instructions, Section IV.B.(g), for detailed instructions.

○ Extramural Subaward: Complete the Research & Related Subaward Budget Form and upload through Grants.gov.

○ Intramural DOD Subaward: Complete a separate “Suggested Intragovernmental/Intramural Budget Form” for each intramural DOD subaward and upload as a single document titled IGBudget.pdf to Grants.gov as Attachment 11.

II.D.2.c. Applicant Verification of Full Application Submission in eBRAP

Independent of submission type, once the full application is submitted it is transmitted to and processed in eBRAP. At this stage, the PI and organizational representatives will receive an email from eBRAP instructing them to log into eBRAP to review, modify, and verify the full application submission. Verification is strongly recommended but not required. eBRAP will validate full application files against the specific program announcement requirements, and discrepancies will be noted in the “Full Application Files” tab in eBRAP. However, eBRAP does not confirm the accuracy of file content. It is the applicant’s responsibility to review all application components and ensure proper ordering as specified in the program announcement. **The Project Narrative and Research & Related Budget Form cannot be changed after the application submission deadline. If either the Project Narrative or the budget fails eBRAP validation or needs to be modified, an updated full application package must be submitted prior to the full application submission deadline.** Other application components, including subaward budget(s) and subaward budget justification(s), may be changed until the end of the application verification period. The full application cannot be modified once the application verification period ends.
II.D.3. Unique Entity Identifier (UEI) and System for Award Management (SAM)

The applicant organization must be registered as an entity in SAM (https://www.sam.gov/content/home) and receive confirmation of an “Active” status before submitting an application through Grants.gov. Organizations must include the UEI generated by SAM in applications to this funding opportunity.

II.D.4. Submission Dates and Times

The pre-application and application submission process should be started early to avoid missing deadlines. There are no grace periods. Failure to meet either of these deadlines will result in submission rejection.

All submission dates and times are indicated in Section I, Overview of the Funding Opportunity.

II.D.5. Funding Restrictions

The maximum period of performance is 2 years.

The application’s direct costs budgeted for the entire period of performance should not exceed $350,000. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization’s negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization’s negotiated rate.

All direct and indirect costs of any subaward or contract must be included in the direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 2 years.

For this award mechanism, direct costs may be requested for (not all-inclusive):

- Travel in support of multidisciplinary collaborations.
- Costs for one investigator to travel to one scientific/technical meeting per year. The intent of travel costs to scientific/technical meetings is to present project information or disseminate project results from the FY24 DMDRP IDA.

Must not be requested for:

- Clinical trial costs

II.D.6. Other Submission Requirements

Refer to the General Application Instructions, Appendix 2, for detailed formatting guidelines.
II.E. Application Review Information

II.E.1. Criteria

II.E.1.a. Peer Review

To determine technical merit, all applications will be individually evaluated according to the following scored criteria, which are of equal importance:

- **Innovation**
  - To what degree the proposed research is innovative.
  - How well the research proposes a new paradigm, challenges existing paradigms, looks at existing problems from new perspectives, or is otherwise creative in one or more of the following ways; concept or question, research methods or technologies, adaptations of existing methods or technologies, or other ways.
  - Whether the proposed research represents more than an incremental advance upon published data.

- **Impact**
  - How well the proposed research addresses opportunities and challenges in the development of safe and effective therapies that address primary pathology of DMD.
  - The degree to which the proposed study could make a significant impact on accelerating progress toward improving outcomes for individuals with DMD.

- **Research Strategy and Feasibility**
  - How well the scientific rationale supports the project and its feasibility as demonstrated by a critical review and analysis of the literature, relevant preliminary data, and logical reasoning.
  - How well the hypotheses or objectives, aims, experimental design, methods, analyses, data collection, statistical analysis plan, rationale for the statistical methodology, and power analysis (if applicable) are developed.
  - If animal studies are included, how well they are designed in accordance with the ARRIVE guidelines 2.0 to achieve reproducible and rigorous results, including the choice of model and the endpoints/outcomes to be measured.
  - If human subjects or human biological samples will be used, how well the plan for the recruitment of subjects or the acquisition of samples is justified and appropriate to accomplish the proposed work.
If clinical research is proposed, whether the strategy for the inclusion of women and minorities and distribution of proposed enrollment are appropriate for the proposed research.

How well the application acknowledges potential limitations and addresses alternative methods and approaches.

Whether the proposed plan for data sharing includes databases most relevant to DMD (if applicable) and whether the plan describes organizational and technical capabilities sufficient to share project data in a timely manner.

If applicable, whether data will be appropriately reported and documented to support a regulatory filing with the FDA.

**Personnel**

The degree to which the levels of effort by the applicant (minimum of 10% for New Investigators – Transitioning per budget year) and other key personnel are appropriate to ensure the success of this research effort.

Based on the biosketch, how well the applicant’s record of accomplishment demonstrates their ability to accomplish the proposed work.

For New Investigators – Transitioning, to what extent the PI will bring their expertise to the field of DMD and pursue an active line of research in DMD.

In addition, the following criteria will also contribute to the overall evaluation of the application, but will not be individually scored and are therefore termed **unscored criteria**:

**Budget**

Whether the **direct** costs exceed the allowable direct costs as published in the program announcement.

Whether the budget is appropriate for the proposed research.

**Environment**

To what degree the scientific environment is appropriate for the proposed research.

How well the research requirements are supported by the availability of and accessibility to facilities and resources (including collaborative arrangements).

To what degree the quality and extent of organizational support are appropriate.

If applicable, to what degree the intellectual and material property plan is appropriate.
• **Application Presentation**
  
  ○ To what extent the writing, clarity, and presentation of the application components influence the review.

**II.E.1.b. Programmatic Review**

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

• Ratings and evaluations of the peer reviewers

• Relevance to the priorities of the Defense Health Program and FY24 DMDRP, as evidenced by the following:
  
  ○ Adherence to the intent of the funding opportunity
  
  ○ Program portfolio composition with consideration of New and Established Investigators
  
  ○ Relative impact and innovation

**II.E.2. Application Review and Selection Process**

All applications are evaluated by scientists, clinicians, and consumers in a two-tier review process. The first tier is **peer review**, the evaluation of applications against established criteria to determine technical merit, where each application is assessed for its own merit, independent of other applications. The second tier is **programmatic review**, a comparison-based process in which applications with high scientific and technical merit are further evaluated for programmatic relevance. Final recommendations for funding are made to the Commanding General, USAMRDC. The highest-scoring applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in **Section II.E.1.b, Programmatic Review**. Additional information about the two-tier process used by the CDMRP can be found at [https://cdmrp.health.mil/about/2tierRevProcess](https://cdmrp.health.mil/about/2tierRevProcess).

All CDMRP review processes are conducted confidentially to maintain the integrity of the merit-based selection process. Panel members sign a statement declaring that application and evaluation information will not be disclosed outside the review panel. Violations of confidentiality can result in the dissolution of a panel(s) and other corrective actions. In addition, personnel at the applicant or collaborating organizations are prohibited from contacting persons involved in the review and approval process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the organization’s application. Violations by panel members or applicants that compromise the confidentiality of the review and approval process may also result in suspension or debarment from federal awards. Furthermore, the unauthorized disclosure of confidential information of one party to a third party is a crime in accordance with 18 USC 1905.
II.E.3. Integrity and Performance Information

Prior to making an assistance agreement award where the federal share is expected to exceed the simplified acquisition threshold, as defined in 2 CFR 200.1, over the period of performance, the federal awarding agency is required to review and consider any information about the applicant that is available in SAM.

An applicant organization may review SAM and submit comments on any information currently available about the organization that a federal awarding agency previously entered. The federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant’s integrity, business ethics, and record of performance under federal awards when determining a recipient’s qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DoDGARs), Section 22.415.

II.F. Federal Award Administration Information

II.F.1. Federal Award Notices

Each applicant organization and PI will receive email notification when the funding recommendations are posted to eBRAP. At this time, each PI will receive a peer review summary statement on the strengths and weaknesses of the application and an information paper describing the funding recommendation and review process for the DMDRP award mechanisms. The information papers and a list of organizations and PIs recommended for funding are also posted on the program’s page within the CDMRP website.

If an application is recommended for funding, after the email notification is posted to eBRAP, a government representative will contact the person authorized to negotiate on behalf of the recipient organization.

Only an appointed USAMRAA Grants Officer may obligate the government to the expenditure of funds to an extramural organization. No commitment on the part of the government should be inferred from discussions with any other individual. The award document signed by the Grants Officer is the official authorizing document (i.e., assistance agreement).

Intra-DOD obligations of funding will be made according to the terms of a negotiated Inter-Agency Agreement and managed by a CDMRP Science Officer.

Funding obligated to intragovernmental and intramural DOD organizations will be sent through the Military Interdepartmental Purchase Request (MIPR), Funding Authorization Document (FAD), or Direct Charge Work Breakdown Structure processes. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intragovernmental and intramural DOD investigators and collaborators must coordinate receipt and commitment of funds through their respective Resource Manager/Task Area Manager/Comptroller or equivalent Business Official.
An organization may, at its own risk and without the government’s prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new award. For extramural submissions, refer to the General Application Instructions, Section IV.B.(e), Pre-Award Costs section, and for intramural submissions, refer to the General Application Instructions, Section V.A.(e), Pre-Award Costs section, for additional information about pre-award costs.

**If there are technical reporting requirement delinquencies for any existing CDMRP awards at the applicant organization, no new awards will be issued to the applicant organization until all delinquent reports have been submitted.**

**II.F.2. PI Changes and Award Transfers**

Unless otherwise restricted, changes in PI or organization will be allowed on a case-by-case basis, provided the intent of the award mechanism is met.

An organizational transfer of an award will not be allowed in the last year of the (original) period of performance or any extension thereof.

Refer to the General Application Instructions, Appendix 7, Section F, for general information on organization or PI changes.

**II.F.3. Administrative and National Policy Requirements**

Applicable requirements in the DoDGARs found in 32 CFR, Chapter I, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this program announcement.

Refer to the General Application Instructions, Appendix 7, for general information regarding administrative requirements.

Refer to the General Application Instructions, Appendix 8, for general information regarding national policy requirements.

Refer to full text of the latest DoD R&D Terms and Conditions and the USAMRAA Research Terms and Conditions: Addendum to the DoD R&D Terms and Conditions for further information.

Applications recommended for funding that involve animals, human data, human specimens, human subjects, or human cadavers must be reviewed for compliance with federal and DOD animal and/or human subjects protection requirements and approved by the USAMRDC Office of Human and Animal Research Oversight, prior to implementation. This administrative review requirement is in addition to the local Institutional Animal Care and Use Committee, IRB, or Ethics Committee review. Refer to the General Application Instructions, Appendix 6, for additional information.
II.F.4. Reporting

Annual technical progress reports as well as a final technical progress report will be required. Annual and final technical reports must be prepared in accordance with the Research Performance Progress Report.

The Award Terms and Conditions will specify whether additional and/or more frequent reporting is required.

Award Expiration Transition Plan: An Award Expiration Transition Plan must be submitted with the final progress report. Use the one-page template “Award Expiration Transition Plan,” available on the eBRAP “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) under the “Progress Report Formats” section. The Award Expiration Transition Plan must outline whether and how the research supported by this award will progress and must include source(s) of funding, either known or pending.

PHS Inclusion Enrollment Reporting Requirement (only required for clinical research studies and clinical trials): Enrollment reporting on the basis of sex/gender, race, and/or ethnicity will be required with each annual and final progress report. The PHS Inclusion Enrollment Report is available on the “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) in eBRAP.

Awards resulting from this program announcement may entail additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have federal contract, grant, and cooperative agreement awards with a cumulative total value greater than $10M are required to provide information to SAM about certain civil, criminal, and administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with performance of a federal award. These recipients are required to disclose, semiannually, information about criminal, civil, and administrative proceedings as specified in the applicable Representations (see General Application Instructions, Appendix 8, Section B).

II.G. Federal Awarding Agency Contacts

II.G.1. eBRAP Help Desk

Questions regarding program announcement content or submission requirements as well as technical assistance related to pre-application or intramural application submission

Phone: 301-682-5507

Email: help@eBRAP.org
II.G.2. Grants.gov Contact Center

Questions regarding Grants.gov registration and Workspace

   Phone:  800-518-4726; International 1-606-545-5035
   Email:  support@grants.gov

II.H. Other Information

II.H.1. Program Announcement and General Application Instructions Versions

Questions related to this program announcement should refer to the program name, the program announcement name, and the program announcement version code 901a. The program announcement numeric version code will match the General Application Instructions version code 901.

II.H.2. Administrative Actions

After receipt of full applications, the following administrative actions may occur.

II.H.2.a. Rejection

The following will result in administrative rejection of the full application:

- Pre-application was not submitted.
- Project Narrative exceeds page limit.
- Project Narrative is missing.
- Budget is missing.

II.H.2.b. Modification

- Pages exceeding the specific limits will be removed prior to review for all documents other than the Project Narrative.
- Documents not requested will be removed.

II.H.2.c. Withdrawal

The following may result in administrative withdrawal of the full application:

- An FY24 DMDRP Programmatic Panel member is named as being involved in the research proposed or is found to have assisted in the pre-application or application processes including, but not limited to, concept design, application development, budget preparation, and the development of any supporting documentation, including letters of support/recommendation.
A list of the FY24 DMDRP Programmatic Panel members can be found at https://cdmrp.health.mil/dmdrp/panels/panels24.

- The application fails to conform to this program announcement description.

- Inclusion of URLs, with the exception of links in References Cited and Publication and/or Patent Abstract sections.

- Applications that include names of personnel from either of the CDMRP peer or programmatic review companies. For FY24, the identities of the peer review contractor and the programmatic review contractor may be found at the CDMRP website (https://cdmrp.health.mil/about/2tierRevProcess).

- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review or approval process to gain protected evaluation information or to influence the evaluation process.

- Applications from extramural organizations, including non-DOD federal agencies, received through eBRAP.

- Applications submitted by a federal government organization (including an intramural DOD organization) may be withdrawn if (a) the organization cannot accept and execute the entirety of the requested budget in current fiscal year (FY24) funds and/or (b) the federal government organization cannot coordinate the use of contractual, assistance, or other appropriate agreements to provide funds to collaborators.

- Application includes research data that are classified and/or proposes research that may produce classified outcomes, or outcomes deemed sensitive to national security concerns.

- Submission of the same research project to different funding opportunities within the same program and fiscal year.

- A clinical trial is proposed.

- The PI does not meet the eligibility criteria.

II.H.2.d. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the USAMRAA Grants Officer for a determination of the final disposition of the application.
### II.H.3. Full Application Submission Checklist

<table>
<thead>
<tr>
<th>Full Application Components</th>
<th>Uploaded</th>
</tr>
</thead>
</table>
| SF424 Research & Related Application for Federal Assistance  
*(Extramural submissions only)* | ☐ |
| Summary (Tab 1) and Application Contacts (Tab 2)  
*(Intramural submissions only)* | ☐ |
| **Attachments** | |
| Project Narrative – Attachment 1, upload as “ProjectNarrative.pdf” | ☐ |
| Supporting Documentation – Attachment 2, upload as “Support.pdf” | ☐ |
| Technical Abstract – Attachment 3, upload as “TechAbs.pdf” | ☐ |
| Lay Abstract – Attachment 4, upload as “LayAbs.pdf” | ☐ |
| Statement of Work – Attachment 5, upload as “SOW.pdf” | ☐ |
| Impact Statement – Attachment 6, upload as “Impact.pdf” | ☐ |
| Innovation Statement – Attachment 7, upload as “Innovation.pdf” | ☐ |
| Data and Research Resources Sharing Plan – Attachment 8, upload as “Sharing.pdf” | ☐ |
| Letter of Eligibility *(New Investigator – Early Stage Only)* – Attachment 9, upload as “Eligibility.pdf” | ☐ |
| Representations *(Extramural Submissions Only)* – Attachment 10, upload as “RequiredReps.pdf” | ☐ |
| Suggested Intragovernmental/Intramural Budget Form *(if applicable)* – Attachment 11, upload as “IGBudget.pdf” | ☐ |
| **Research & Related Personal Data** | ☐ |
| **Research & Related Senior/Key Person Profile (Expanded)** | ☐ |
| Attach PI Biographical Sketch (Biosketch_LastName.pdf) | ☐ |
| Attach PI Previous/Current/Pending Support (Support_LastName.pdf) | ☐ |
| Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person | ☐ |
| Attach Previous/Current/Pending (Support_LastName.pdf) for each senior/key person | ☐ |
| **Research & Related Budget *(Extramural submissions only)*** | ☐ |
| Include budget justification | ☐ |
| **Budget *(Intramural submissions only)*** | ☐ |
| Include budget justification | ☐ |
| **Project/Performance Site Location(s) Form** | ☐ |
| **Research & Related Subaward Budget Attachment(s) Form *(if applicable)*** | ☐ |
APPENDIX 1: ACRONYM LIST

ACOS/R&D  Associate Chief of Staff for Research and Development
ACURO  Animal Care and Use Review Office
ARRIVE  Animal Research: Reporting In Vivo Experiments
CDMRP  Congressionally Directed Medical Research Programs
CFR  Code of Federal Regulations
DMD  Duchenne Muscular Dystrophy
DMDRP  Duchenne Muscular Dystrophy Research Program
DOD  Department of Defense
DoDGARs  Department of Defense Grant and Agreement Regulations
eBRAP  Electronic Biomedical Research Application Portal
ET  Eastern Time
FAD  Funding Authorization Document
FDA  Food and Drug Administration
FY  Fiscal Year
IDA  Idea Development Award
IRB  Institutional Review Board
LOI  Letter of Intent
M  Million
MIPR  Military Interdepartmental Purchase Request
NIH  National Institutes of Health
PDF  Portable Document Format
PHS  Public Health Service
PI  Principal Investigator
SAM  System for Award Management
SOW  Statement of Work
UEI  Unique Entity Identifier
URL  Uniform Resource Locator
USAMRAA  U.S. Army Medical Research Acquisition Activity
USAMRDC  U.S. Army Medical Research and Development Command
USC  United States Code
VA  U.S. Department of Veterans Affairs